Streetbeat News

Price Targets

EWTX

Truist Securities analyst Srikripa Devarakonda has reaffirmed a Buy rating on Edgewise Therapeutics (NASDAQ:EWTX) and maintained a price target of $25.

Portfolio Pulse from Benzinga Newsdesk

April 17, 2024 | 5:19 pm

NBIX

Wedbush analyst Laura Chico reiterates an Outperform rating on Neurocrine Biosciences (NBIX) and maintains a $147 price target.

Portfolio Pulse from Benzinga Newsdesk

April 17, 2024 | 5:19 pm

HD

Truist Securities analyst Scot Ciccarelli has maintained a Buy rating on Home Depot (HD) with a price target of $417.

Portfolio Pulse from Benzinga Newsdesk

April 17, 2024 | 5:18 pm

ACN

Recent options market activity indicates a bearish sentiment towards Accenture (NYSE:ACN), with a notable volume of trades suggesting expectations for the stock's price to range between $310.0 and $330.0. Analysis of the largest trades reveals a mix of bullish, bearish, and neutral positions. Accenture, a global IT-services firm, has seen its stock price slightly decrease to $313.89. Analysts have varied opinions, with a consensus target price of $400.6, but recent adjustments include a downgrade by Mizuho to Buy with a target of $398.

Portfolio Pulse from Benzinga Insights

April 17, 2024 | 5:16 pm

JNJ

RBC Capital analyst Shagun Singh maintains an Outperform rating on Johnson & Johnson (JNJ) but lowers the price target from $181 to $175.

Portfolio Pulse from Benzinga Newsdesk

April 17, 2024 | 5:11 pm

NFLX

BMO Capital Markets analyst Brian J. Pitz reaffirmed an Outperform rating on Netflix, Inc. (NASDAQ:NFLX), raising the price target from $638 to $713, citing potential for member growth and operating margin expansion from 2024 onwards. Pitz highlights initiatives like paid sharing and T-Mobile ad tier shift, along with content innovation, as key drivers. He estimates Netflix will capture a significant share of linear TV dollars shifting online, with advertising expected to make up about 10% of total revenue by 4Q25. Netflix is anticipated to have over 41 million AVOD members by FY24, growing to over 54 million by FY25.

Portfolio Pulse from Nabaparna Bhattacharya

April 17, 2024 | 5:11 pm

VC

Guggenheim analyst Ronald Jewsikow maintains a Buy rating on Visteon (NASDAQ:VC) but lowers the price target from $136 to $126.

Portfolio Pulse from Benzinga Newsdesk

April 17, 2024 | 5:06 pm

LAD

Guggenheim analyst Ronald Jewsikow maintains a Buy rating on Lithia Motors (LAD) but lowers the price target from $320 to $297.

Portfolio Pulse from Benzinga Newsdesk

April 17, 2024 | 5:05 pm

GNTX

Guggenheim analyst Ronald Jewsikow has maintained a Buy rating on Gentex (NASDAQ:GNTX) and increased the price target from $40 to $41.

Portfolio Pulse from Benzinga Newsdesk

April 17, 2024 | 5:03 pm

AMPL

Amplitude (NASDAQ:AMPL) has been reviewed by 4 analysts in the past three months, showing a mix of neutral and somewhat bearish perspectives. The average 12-month price target is now $11.5, down from $13.00, indicating a negative sentiment shift. Analysts from Morgan Stanley and Citigroup have adjusted their price targets and ratings, reflecting concerns over Amplitude's market performance. Despite a solid revenue growth rate of 9.42% and a strong market presence, Amplitude's financial indicators such as net margin and ROA suggest areas of challenge.

Portfolio Pulse from Benzinga Insights

April 17, 2024 | 5:01 pm